Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management

被引：0
|
作者：
Pierre-Yves Courand
Mathilde Berger
Anissa Bouali
Brahim Harbaoui
Pierre Lantelme
Stéphane Dalle
机构：
[1] Hôpital de La Croix-Rousse Et Hôpital Lyon Sud,Fédération de Cardiologie
[2] Hospices Civils de Lyon,Université de Lyon, CREATIS, CNRS UMR5220, INSERM U1044, INSA
[3] Université Claude Bernard Lyon 1,Lyon
[4] Hôpital de Lyon Sud,Service de Dermatologie
来源：
Current Oncology Reports | 2022年 / 24卷
关键词：
Melanoma; Cardiac toxicity; BRAF inhibitor; MEK inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：265 / 271
页数：6
相关论文
共 50 条
  • [1] Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management
    Courand, Pierre-Yves
    Berger, Mathilde
    Bouali, Anissa
    Harbaoui, Brahim
    Lantelme, Pierre
    Dalle, Stephane
    [J]. CURRENT ONCOLOGY REPORTS, 2022, 24 (03) : 265 - 271
  • [2] Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors
    Arangalage, Dimitri
    Degrauwe, Nils
    Michielin, Olivier
    Monney, Pierre
    Ozdemir, Berna C.
    [J]. CANCER TREATMENT REVIEWS, 2021, 100
  • [3] Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma
    Sibaud, Vincent
    Baric, Lilian
    Cantagrel, Alain
    Di Palma, Mario
    Ederhy, Stephane
    Paques, Michel
    Perlemuter, Gabriel
    [J]. BULLETIN DU CANCER, 2021, 108 (05) : 528 - 543
  • [4] Inflammatory side effects of BRAF and MEK inhibitors
    Mackin, Anna G.
    Pecen, Paula E.
    Dinsmore, Amanda L.
    Patnaik, Jennifer L.
    Gonzalez, Rene
    Robinson, William A.
    Palestine, Alan G.
    [J]. MELANOMA RESEARCH, 2019, 29 (05) : 522 - 526
  • [5] Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors
    Bronte, Enrico
    Bronte, Giuseppe
    Novo, Giuseppina
    Rinaldi, Gaetana
    Bronte, Fabrizio
    Passiglia, Francesco
    Russo, Antonio
    [J]. PHARMACOLOGY & THERAPEUTICS, 2018, 192 : 65 - 73
  • [6] BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management
    Livingstone, Elisabeth
    Zimmer, Lisa
    Vaubel, Julia
    Schadendorf, Dirk
    [J]. CHINESE CLINICAL ONCOLOGY, 2014, 3 (03)
  • [7] Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
    Kuske, Marvin
    Westphal, Dana
    Wehner, Rebekka
    Schmitz, Marc
    Beissert, Stefan
    Praetorius, Christian
    Meier, Friedegund
    [J]. PHARMACOLOGICAL RESEARCH, 2018, 136 : 151 - 159
  • [8] BRAF and MEK inhibitors in BRAF-mutant melanoma
    Sharma, Sharan Prakash
    [J]. LANCET ONCOLOGY, 2012, 13 (11): : E468 - E468
  • [9] Immune-based Anti-tumor Effects of BRAF Inhibitors/MEK Inhibitors
    Kuske, M.
    Praetorius, C.
    Westphal, D.
    Meier, F.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 41 - 41
  • [10] Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors forMetastatic Melanoma
    Carlos, Giuliana
    Anforth, Rachael
    Clements, Arthur
    Menzies, Alexander M.
    Carlino, Matteo S.
    Chou, Shaun
    Fernandez-Penas, Pablo
    [J]. JAMA DERMATOLOGY, 2015, 151 (10) : 1103 - 1109
12345